When times got tough, the bio­phar­ma in­dus­try hit the Zoom but­ton and kept things mov­ing at a multi­bil­lion-dol­lar clip

Don’t ever un­der­es­ti­mate bio­phar­ma’s abil­i­ty to grab ahold of an op­por­tu­ni­ty, even if they can’t close a deal with a hand­shake.

While re­tail and oth­er in­dus­tries strug­gle to sur­vive a vi­cious down­turn brought on by the pan­dem­ic, bio­phar­ma con­tin­ues to make fresh gains — or stay on an el­e­vat­ed track — on most deal­mak­ing fronts. And this new set of charts from Deal­For­ma chief Chris Doko­ma­ji­lar un­der­scores the height­ened lev­el of ac­tiv­i­ty this past spring.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER